Renalytix Share Discussion Threads

[wan] 06/5/2021 10:05

My view FWIW, continues to be that Kantaro will, at some point, represent another spin off opportunity.

[mr roper] 06/5/2021 09:49

I’ve pretty much discounted it completely. Antibody testing will probably come into fashion later this year. Can’t see it being a huge contributor but happy to be proved wrong. Otherwise, it seems to be all eyes on May 15th...

[donald pond] 06/5/2021 09:46

We have no idea what level of sales that kantaro product has achieved or the revenue implications for RENX though. Kantaro could end up being another spin off I'd have thought

[wan] 05/5/2021 07:54

In case it was missed -

Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards

04/05/2021 7:20pm
PR Newswire (US)

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 World Changing Ideas Awards.

[wan] 02/5/2021 06:31

Homebrewruss....Thank you for highlighting the AstraZeneca news.

From my post 1002 -

Staying with AstraZeneca, and the collaboration with Renalytix -

21 August 2020

The first stage will assess the impact of AI-enabled in vitro diagnostic solutions to optimize utilization of therapeutics in CKD under current standard of care protocols. Based on study outcomes, a multi-center, randomized controlled trial will be initiated to evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalemia. The studies will be conducted in coordination with the Mount Sinai Health System, where KidneyIntelX testing and care management software are currently being deployed for commercial clinical use.

“We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases, such as kidney disease, diabetes, and cardiovascular disease,â€ʏ33; said Barbara Murphy, MD, Chair of the Samuel Bronfman Department of Medicine, Dean for Clinical Integration and Population Health Management at the Icahn School of Medicine at Mount Sinai, and board member of RenalytixAI. “By using a more personalized approach, our initial goal is to help realize improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.â€ᦙ3;

RenalytixAI and AstraZeneca will use KidneyIntelX with the aim to:

Help improve physician uptake and patient adherence to existing potassium-binding therapeutics and other approved products in CKD through early identification of previously hidden high-risk patient groups

Accelerate patient identification and recruitment for clinical trials

Complement commercialization efforts with outcomes from KidneyIntelX results

“This collaborative approach reflects the shared vision of AstraZeneca and RenalytixAI to develop meaningful solutions to tackle significant challenges in healthcare in a holistic way,� said Tarek Rabah, Vice President, AstraZeneca US Renal-Cardio. “We are committed to revolutionizing kidney care by continuing to drive innovation. An important component of our work is identifying patients with significant unmet need and providing them with more personalized interventions.�

Results from the program are anticipated in early 2021.



What also caught my attention recently was Renalytix completion of the first stage of their statement of work with AstraZeneca, but not specifically RNS'd was the fact that in December 2020 Renalytix entered into a master service agreement with AstraZeneca for future services. Excerpt follows from the Half-year Report dated 2 March 2021 -

Additionally, we have successfully completed the first stage of our statement of work with AstraZeneca Pharmaceuticals LP (“AstraZeneca�;) to conduct a feasibility study to determine the impact of the use of our KidneyIntelX platform to optimize utilization of various CKD agents. Further, in December 2020 we entered into a master service agreement with AstraZeneca for future services of this nature. We believe this agreement will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases such as kidney disease, diabetes, and cardiovascular disease. Building on our initial success with AstraZeneca, we plan to pursue further collaborations with pharmaceutical companies and make ‘Pharmaceutical Services Revenue’ a core part of our business going forward with the goal of improving guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.
(END) -
Page 5 -

Results from the program were anticipated in early 2021, but there may have been a delay from the effects of COVID-19 on Mount Sinai, which is understandable. Given hospital patient volume is recovering in the US, we may not have too long to wait before the results are published/released.

[mr roper] 01/5/2021 18:14

Yup. Good news on the ckd front. Next frontier for Renx. Hopefully extending KidneyIntelX to ckd in 2022. Pretty sure the partnership with Astra can only help.

[homebrewruss] 01/5/2021 15:51

'AstraZeneca’s FARXIGA® (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.'

[golfnut59] 27/4/2021 12:22

nice write up on RENX here:

www.uksmallcapstocks.com/f/renalytixai-renx

[wan] 27/4/2021 07:41

On no new news, it would appear that the implications from the recently announced contract, along with the pending FDA approval, are starting to be better understood/appreciated.

[mr roper] 26/4/2021 21:25

New closing high for $rnlx on double average daily volume. Nice.

[mr roper] 26/4/2021 18:03

New 52wk high hit Stateside. Good volume again

[mr roper] 26/4/2021 17:16

Highest daily close today. Nice to see.

[mr roper] 25/4/2021 09:03

MCIT enables Innovative Tech to be covered from day 1 of fda approval. The normal Medicare route is a slower route to revenue generation

“..with the current Medicare coverage options, we have had challenges keeping national Medicare coverage on pace with these innovations because of the availability of clinical evidence required to approve technologies through the NCD process. To respond to this challenge, and following the EO 13890, CMS is finalizing MCIT to create a more efficient coverage pathway for breakthrough devices. “

hxxps://www.cms.gov/newsroom/fact-sheets/medicare-coverage-innovative-technology-cms-3372-f

[golfnut59] 25/4/2021 08:29

I've been doing a lot of research on RENX over the weekend. The only thing that is confusing me a little is how have the company been able to agree a GWAC contract offered through the GSA without FDA approval? Not only this but getting the MCIT ruling passed would seem critical as the Veterans Administration advises its beneficiaries to also have medicare. Also, does anyone know the current testing capacity. How many tests are the company currently able to perform per month?

[mr roper] 24/4/2021 21:52

The best part, mf, is that’s only the US market. 850m folk globally with kidney disease. If Renx become the go to for kidney diagnostics how long until The rest of the world follow.

US medical spending on kidney disease is in the ballpark of $120-140bn a year!

I think this contract is a step change for the company.

[donald pond] 24/4/2021 21:27

I did some digging on Thursday and the average annual cost of dialysis in the US is $90,000 pa and a kidney transplant is $440k and fraught with riskSo you do the maths and $950 a test is an absolute no brainer for anyone picking up healthcare bills. And 80m US citizens are deemed at risk of kidney disease and veterans are at a 30% greater risk than the general population It's not a huge leap to see at least 1m tests a year, and with a 70-80% margin that would be $650-750m annual profit. But you could multiply that by 10, and that's just in the US. Extraordinary possibilities but the key is to understand how much it can save if it avoids people finding out their kidneys are at risk at the point where dialysis and transplants are the only remedy

[hpcg] 24/4/2021 20:46

nimbo1 - in terms of cost benefit the diagnostic tool is dramatic. When people are still at the start of their "need a new kidney" journey, for want of a better term, the cost of preventions, which are all lifestyle, are free. Apart from the dishonest doctors that want the extra business, and yes sadly they do exist, it is a no-brainer for everyone that is overweight.

I agree with you about risk reward; I bought more earlier in the week. Averaging up much better than averaging down.

[rampmeister] 24/4/2021 17:58

Does a know how much of the $ 950 becomes gross operating profit?

RM

[mr roper] 24/4/2021 16:04

If they execute the revenue generation part of the plan as well as they have they infrastructure and partnerships I can see a path to a $10bn valuation. If anything they seem to be picking up momentum.

The contract announced on Thursday went live on the 15th so we should see the first sign of revenue in the Q2 reporting due around September time from memory.

If we receive fda approval alongside mcit coming in on May15th then we could be in for a bumper end to the year.

That’s excluding everything else going on...clinical studies, further partnerships etc

[nimbo1] 24/4/2021 13:44

I think the article makes a lot of sense. I found renx at 3.5 and sold my holding around the time of the nasdaq float.

My concerns were around how easy (hard) it is to get new test adopted and speed of adoption. So far management have been executing with excellence and the ease of gaining partnerships is I think a reflection of how essential this test is perceived at improving the kidney care clinical pathway.

I also think given all the news flow and operational progress made to date it is less risky buying around here than it was buying at £6-7 before any of the news from the last couple of months.

Just my 2 pennies worth (and im a holder again : ))

[mr roper] 23/4/2021 23:10

Looks like a breakout on the daily $rnlx chart. Good stuff

[newbold120] 23/4/2021 21:19

Nice close on Nasdaq

[mr roper] 23/4/2021 14:38

Mcit comes in on May 15th. Fda this year is guidance from Renx.

[golfnut59] 23/4/2021 13:27

Thank you so much. You've been a great help.

When are we likely going to hear from the FDA and what's the likelihood of the MCIT ruling going in our favour?